Acthar as Rescue Therapy for Transplant Glomerulopathy in Kidney Transplant Recipients
Acthar as Rescue Therapy for Transplant Glomerulopathy in Kidney Transplant Recipients
The goal of this study is to evaluate the benefit of ACTH (Acthar) in reducing proteinuria
 associated with transplant glomerulopathy in non-diabetic kidney transplant recipients.
Inclusion Criteria:

 -  Kidney transplant recipients with confirmed transplant glomerulopathy on kidney
 biopsy.

 -  Failed standard therapy (>25% reduction in proteinuria) including maximum use of an
 ACE inhibitor, ARB, or aldosterone blocker with a goal blood pressure less than 130/80
 and optimization of their immunosuppression

 Exclusion Criteria:

 -  Diabetes